278 related articles for article (PubMed ID: 30236079)
1. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
Kiselev VI; Ashrafyan LA; Muyzhnek EL; Gerfanova EV; Antonova IB; Aleshikova OI; Sarkar FH
BMC Cancer; 2018 Sep; 18(1):904. PubMed ID: 30236079
[TBL] [Abstract][Full Text] [Related]
2. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
4. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Trudel D; Labbé DP; Araya-Farias M; Doyen A; Bazinet L; Duchesne T; Plante M; Grégoire J; Renaud MC; Bachvarov D; Têtu B; Bairati I
Gynecol Oncol; 2013 Nov; 131(2):357-61. PubMed ID: 23988418
[TBL] [Abstract][Full Text] [Related]
5. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
6. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
El-Husseiny K; Motawei H; Ali MS
Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
9. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
Liutkauskiene S; Janciauskiene R; Jureniene K; Grizas S; Malonyte R; Juozaityte E
BMC Cancer; 2015 Mar; 15():105. PubMed ID: 25879527
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
12. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
13. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
14. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
Eisenhauer EL; Tew WP; Levine DA; Lichtman SM; Brown CL; Aghajanian C; Huh J; Barakat RR; Chi DS
Gynecol Oncol; 2007 Aug; 106(2):381-7. PubMed ID: 17509673
[TBL] [Abstract][Full Text] [Related]
15. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
Pant AC; Diaz-Montes T; Tanner E; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE
J Chemother; 2010 Aug; 22(4):270-4. PubMed ID: 20685633
[TBL] [Abstract][Full Text] [Related]
16. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
17. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
18. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
[TBL] [Abstract][Full Text] [Related]
20. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Chen X
Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
